Abstract: A new series of morpholinyl-chalcones 2a-d was prepared by reaction of 2-oxo-N,4-diarylbut-3-enehydrazonoyl chlorides 1a-d with morpholine. These chalcones were used as a building block for constructing pyrazoles 3a-d and 3,4-dihydropyrimidine-2(1H)-thione 6 via their reaction with phenylhydrazine and thiourea, respectively. Moreover, a new series of azolopyrimidine derivatives 11a,b, 15, 17, 19, and 21 incorporating morpholine moiety were synthesized by reaction of 1-morpholino-4-phenyl-1-(2-phenylhydrazono)but-3-en-2-one (2a) with a number of heterocyclic amines in the presence of a catalytic amount of acetic acid. The assigned structures for all the newly synthesized compounds were confirmed on the basis of elemental analyses and spectral data and the mechanisms of their formation were also discussed.
INTRODUCTION
YDRAZONOYL halides are compounds which have the characteristic functionality -C(X):NNH-, where X is a halogen (Br or Cl). An increasing flow of work has appeared on the chemistry of such a class of compounds. They have recently reawaken interest in their chemistry as they proved to be useful building blocks for one-pot synthesis of a wide variety of heterocycles such as 1,3-thiazoles, [1] [2] [3] [4] 1,3,4-thiadiazoles, [5, 6] pyrazoles, pyrazolo [3,4-d] pyridazines, [7, 8] triazolo [4,3-b] triazinones, [9, 10] triazolo [3,4-b] thiadiazines, triazolo [4,3-b] tetrazines, [11] [12] [13] 1,2,4-triazolo-pyrimidinones, [14] [15] [16] pyrimido-tetrazinones, pyrimido-thiadiazinones [17] and benzopyranotriazepines. [18] Literature reveals that morpholine derivatives have found great significance in modern years due to their variety of pharmacological activities including anticancer, anti-inflammatory, analgesic, antidepressant, antifungal, anti-parasitic, antiplatelet, anti-tuberculosis, HIV-protease inhibitors, selective inhibitor of protein kinase C, neuroprotective and anti-malarial. [19] [20] [21] [22] [23] In addition, many pyrimidines and triazolopyrimidines are pharmacological scaffolds displaying a wide range of biological activities such as anticancer, antimicrobial, hypoglycemic, CNS depressant, antiallergy, antiinflammatory, and diuretic activities. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] On the other hand, pyrazoles have been reported to possess a variety of significant and diverse pharmacological activities such as antibacterial, antifungal, anticonvulsant, antiviral, antitubercular, antidepressant, anti-inflammatory, antiamoebic, analgesic and anticancer activity. [34] [35] [36] [37] [38] [39] In view of all these reports and in continuation of our previous work in synthesis of bioactive heterocyclic compounds, [40] [41] [42] [43] [44] [45] [46] [47] herein, we are interested in synthesizing a new series of pyrazoles and azolopyrimidines using morpholinylchalcones as common precursor and evaluate these compounds for their anticancer activities.
H Synthesis of Pyrazoles 3a-d
A mixture of chalcones 2a-d (1 mmol) and phenylhydrazine (0.108 g, 1 mmol) in 15 mL of ethanol containing 1 mL of glacial acetic acid was refluxed for 4-10 h (monitored through TLC). The desired product precipitated from reaction mixture was filtered, washed with ethanol and recrystallized from proper solvent to give the respective pyrazoles 3a-d, respectively. C22H18N4O (354.41): C, 74.56; H, 5.12; N, 15.81. Found: C, 74.39; H, 5.18; N, 15.65 %. N',1-DIPHENYL-3-(P-TOLYL)-1H-PYRAZOLE-5-CARBOHYDRAZIDE (3b) Orange solid, (60 % yield), mp 203-205 °C (EtOH); IR (KBr) νmax 1597 (C=N), 1671 (C=O), 3050, 2928 (C-H), 3263, 3420 (2NH) cm -1 ; 1 H NMR (DMSO-d6) δ 2.35 (s, 3H, CH3), 6.68-7.16 (m, 10H, Ar-H), 7.24 (s, 1H, pyrazole-H4), 7.31-7.76 (m, 4H, Ar-H), 9.58 (brs, 1H, NH), 9.81 (brs, 1H, NH); 13 C-NMR (DMSO-d6): δ 21.1 (CH3), 112.3, 120.3, 121.0, 121.9, 123.5, 126.1, 126.9, 127.4, 127.9, 128.2, 130.5, 132.7, 133.9, 139.4, 168.7 (C=O) ; MS m / z (%) 368 (M + , 7), 321 (9), 291 (3), 275 (4), 233 (4), 208 (5), 178 (3), 119 (40), 106 (45), 91 (100), 77 (37), 43 (75). Anal. Calcd. for C23H20N4O (368.44): C, 74.98; H, 5.47; N, 15.21. Found: C, 74.75; H, 5.62; N, 14 .99 %. 111.6, 112.0, 118.2, 120.5, 121.3, 124.6, 126.2, 126.8, 128.4, 128.8, 130.4, 133.5, 135.9, 149.2, 
3-(4-CHLOROPHENYL)-N',1-DIPHENYL-1H-PYRAZOLE-

SYNTHESIS OF 6-(MORPHOLINO-(2-PHENYLHYDRAZONO)METHYL)-4-PHENYL-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONE (6)
A mixture of 1-morpholino-4-phenyl-1-(2-phenylhydrazono)but-3-en-2-one (2a) (3.35 g, 10 mmol) and thiourea (0.76 g, 10 mmol) in 40 mL of ethanol containing catalytic amount of potassium hydroxide was refluxed for 6 h (monitored through TLC). The reaction mixture was then poured into 2 N HCl, and the solid product was collected by filtration followed by washing with water and EtOH. The crude product was recrystallized from DMF to give pure product of compound 6 as yellowish-white solid in 75 % yield, IR (KBr) GENERAL PROCEDURE Triethylamine (0.14 mL, 1 mmol) was added to a mixture of equimolar amounts of thione 6 (0.393 g, 1 mmol) and the appropriate hydrazonoyl halides 7a-d (1 mmol) in dioxane (20 mL) at room temperature. The reaction mixture was refluxed till all of the starting materials have been disappeared and hydrogen sulfide gas ceased to evolve (6-10 h, monitored by TLC). The solvent was evaporated and the residue was triturated with methanol. The solid that formed was filtered and recrystallized from the proper solvent to give the products 8a-d, respectively. 113.7, 117.3, 121.2, 122.0, 122.6, 123.3, 124.8, 126.3, 128.2, 128.9, 129.1, 130.2, 132.7, 133.0, 136.2, 139.7, 151.4 114.8, 116.3, 120.3, 120.4, 120.3, 122.3, 123.3, 124.5, 124.9, 126.8, 128.7, 128.8, 129.2, 129.3, 129.4, 140.9, 
1-(7-(MORPHOLINO(2-PHENYLHYDRAZONO
General Method for Synthesis of Compounds 11a,b, 15, 17, 19 and 21
A mixture of each of 1-morpholino-4-phenyl-1-(2-phenylhydrazono)but-3-en-2-one (2a) (0.335 g, 1 mmol) and the appropriate heterocyclic amine (9a,b, 14, 16, 18 or 20) (1 mmol) in ethanol (20 mL) in the presence of catalytic drops of acetic acid was refluxed for 10-15 h (monitored through TLC). The reaction mixture was poured into water and the solid product was collected by filtration followed by washing with ethanol. The crude product was then recrystallized from DMF to give pure products of 115.2, 117.0, 119.2, 121.5, 122.0, 125.3, 127.9, 129.1, 130.3, 132.4, 132.9, 137.5, 144.6, 158. 115.7, 118.3, 120.1, 120.5, 122.3, 124.1, 124.8, 126.9, 126.9, 129.4, 130.3, 130.8, 133.6, 134.5, 134.8, 137.1, 139.2, 141.6, 159.6 
Evaluation of Cytotoxic Effects of Compounds MAMMALIAN CELL LINES
CHEMICALS USED
Dimethyl sulfoxide (DMSO), crystal violet and trypan blue dye were purchased from Sigma (St. Louis, Mo., USA).
Fetal Bovine serum, DMEM, RPMI-1640, HEPES buffer solution, L-glutamine, gentamycin and 0.25 % Trypsin-EDTA were purchased from Lonza.
CRYSTAL VIOLET STAIN (1 %)
It composed of 0.5 % (w / v) crystal violet and 50 % methanol then made up to volume with ddH 2O and filtered through a Whatmann No.1 filter paper.
CELL LINE PROPAGATION
The cells were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % heat-inactivated fetal bovine serum, 1 % L-glutamine, HEPES buffer and 50 µg mL -1 gentamycin. All cells were maintained at 37 °C in a humidified atmosphere with 5 % CO2 and were subcultured two times a week.
CYTOTOXICITY EVALUATION USING VIABILITY ASSAY
For cytotoxicity assay, the cells were seeded in 96-well plate at a cell concentration of 1 × 10 4 cells per well in 100µl of growth medium. Fresh medium containing different concentrations of the test sample was added after 24 h of seeding. Serial two-fold dilutions of the tested chemical compound were added to confluent cell monolayers dispensed into 96-well, flat-bottomed microtiter plates DOI: 10.5562/cca3279
Croat. Chem. Acta 2018, 91(1), 43-51 (Falcon, NJ, USA) using a multichannel pipette. The microtiter plates were incubated at 37 °C in a humidified incubator with 5 % CO2 for a period of 48 h. Three wells were used for each concentration of the test sample. Control cells were incubated without test sample and with or without DMSO. The little percentage of DMSO present in the wells (maximal 0.1 %) was found not to affect the experiment. After incubation of the cells for at 37 °C, various concentrations of sample were added, and the incubation was continued for 24 h and viable cells yield was determined by a colorimetric method. In brief, after the end of the incubation period, media were aspirated and the crystal violet solution (1 %) was added to each well for at least 30 minutes. The stain was removed and the plates were rinsed using tap water until all excess stain is removed. Glacial acetic acid (30 %) was then added to all wells and mixed thoroughly, and then the absorbance of the plates were measured after gently shaken on Microplate reader (TECAN, Inc.), using a test wavelength of 490 nm. All results were corrected for background absorbance detected in wells without added stain. Treated samples were compared with the cell control in the absence of the tested compounds. All experiments were carried out in triplicate. The cell cytotoxic effect of each tested compound was calculated. The optical density was measured with the microplate reader (SunRise, TECAN, Inc, USA) to determine the number of viable cells and the percentage of viability was calculated as [1-(ODt/ODc)] × 100 % where ODt is the mean optical density of wells treated with the tested sample and ODc is the mean optical density of untreated cells. The relation between surviving cells and drug concentration is plotted to get the survival curve of each tumor cell line after treatment with the specified compound. The 50 % inhibitory concentration (IC50), the concentration required to cause toxic effects in 50 % of intact cells, was estimated from graphic plots of the dose response curve for each conc. using Graphpad Prism software (San Diego, CA. USA). [48] 
RESULTS AND DISCUSSION
As previously described, [49] compounds 1a-d reacted with morpholine in ethanol under reflux for 3-6 hrs to give the morpholinohydrazonobutenone derivatives 2a-d (Scheme 1), which were used as a precursors for synthesis of pyrazoles, pyrimidines, and different fused pyrimidines, such as triazolopyrimidine, tetrazolopyrimidine, thiazolopyrimidine, benzothiazolo-pyrimidine benzoimidazopyrimidine, and pyridopyrazolopyrimidine derivatives.
Compounds 2a-d were refluxed in ethanol containing catalytic amount of acetic acid with phenylhydrazine for 4-10 hrs affording the corresponding pyrazole derivatives 3a-d, rather than the compounds 4a-d (Scheme 1), what was confirmed based on the mass spectrum and IR spectrum which showed a peak at 1715 cm -1 that revealed the presence of amidic carbonyl group. All the spectral data and elemental analyses of these compounds were in agreement with the proposed structures (see Experiment).
On the other hand, morpholinohydrazinophenylbutenone derivative 2a was heated under reflux with thiourea (5) and gave the 6-(morpholino(2-phenylhydrazono)methyl)-4-phenyl-3,4-dihydropyrimidine-2(1H)-thione (6) (Scheme 2).
Furthermore, compound 6 with hydrazonoyl chlorides 7a-d afforded the corresponding sulphur free compounds pyridotriazolopyrimidine 8a-d (Scheme 2). IR spectrum for 1,5-dihydro-[1,2,4]triazolo[4,3-a]pyrimidinone derivative 8a, as an example, gave peaks at 1650 and 3253 cm -1 that correspond to C=O and NH groups. Compound 2a was then used for preparation of azolopyrimidine compounds via its reactions with a variety of heterocyclic amines. For example, reaction of each of compound 2a with 5-amino-1,2,4-triazole 9a or 5-amino-1,2,3,4-tetrazole 9b in the presence of a catalytic amount of acetic acid under reflux afforded triazolo [1,5-a] pyrimidine derivative 11a and tetrazolo [1,5-a] pyrimidine derivative 11b, respectively (Scheme 3). The structure assigned to these products was confirmed based on elemental analysis and spectroscopic methods (IR, 1 H NMR and mass spectra) (see Experimental). For example, the IR spectra of products 11a revealed an absorption band at υ = 3247 due to hydrazine-NH group. Its 1 H NMR showed signals at δ = 2. 4H, 2CH2), 4H, 2CH2), 10H, 8.01 (s, 1H, 8.19 (s, 1H, 10.65 (brs, 1H, NH) ppm. The mass spectra of products 11a,b revealed a molecular ion peak for each one which is consistent with the respective molecular weight.
The suggested mechanism for the formation of compounds 11a,b was outlined in Scheme 3. It was postulated that the reaction of chalcone 2 with the appropriate heterocyclic amine starts with Michael addition (route a) of the amino group to the double bond of the enone residue of 2a to give intermediate 10 which undergoes in situ dehydrative cyclization followed by autooxidation to give the final azolopyrimidine 11a,b. The spectral data and elemental analyses data are consistent with the regioisomeric structures 11 and 13. The isomeric compounds 13 produced by route b were discarded due to difficultness in condensation reaction than Michael addition (route a). [50, 51] However, an equimolar amount of compound 2a and 2-aminobenzoimidazole 14 were heated under reflux in ethanol containing a catalytic amount of acetic acid to give benzo [4, 5] 
Cytotoxic Activity
The in vitro growth inhibitory activity of the newly synthesized compounds 3a, 6, 8a-d, 11a,b, 15, 17, 19 and 21 was investigated against two carcinoma cell lines, human lung cancer cell line (A-549) and human hepatocellular carcinoma cell line (HepG-2), in comparison with the well-known anticancer standard drug (cisplatin) under the same conditions using colorimetric MTT assay. Data generated were used to plot a dose response curve of which the concentration of test compounds required to kill 50 % of cell population (IC50) was determined. The results are depicted in Table 1 and revealed that the descending order of activity of the newly synthesized compounds towards the lung carcinoma cell line (A549) were as
The descending order of activity of the newly synthesized compounds towards the human Hepatocellular carcinoma cell line (HepG-2) were as follow:
Structure Activity Relationship (SAR)
Examination of the SAR leads to the following conclusions.
The results revealed that all the tested compounds showed inhibitory activity to the tumor cell lines in a concentration dependent manner.
The activities of the synthesized compounds depend on the structural skeleton and electronic environment of the molecules.
Compounds 6 and 8c were the most active (IC50 value of 2.81 ± 0.9, 3.45 ± 5.6 μg mL -1 , respectively) against the lung carcinoma cell line (A549), compared with cisplatin reference drug with IC50 value of 0.95±0.9 μg mL -1 . On the other hand, compounds 8a, 8b, 8d, 3a and 11b have poor inhibitory activity (IC50 > 30 µg mL -1 ) (Figure 1) .
Compounds 6 and 17 were the most active (IC50 value of 2.99 ± 1.8, 5.69 ± 9.8 μg mL -1 , respectively) against the human hepatocellular carcinoma cell line (HepG-2), compared with cisplatin reference drug with IC50 value of 1.40 ± 1.1 μg mL -1 . On the other hand, compounds 8a, 8b and 3a have poor inhibitory activity (IC50 > 30 µg mL -1 ) (Figure 1) .
Among the fused pyrimidine derivatives, triazolopyrimidine 11a is the most active one against the A549 (IC50 = 7.45 ± 0.7 μg mL -1 ) while the pyridopyrazolopyrimidine 17 is the most active one against the HepG-2 cell line (A549) (IC50 = 7.45 ± 0.7 μg mL -1 ).
For triazolopyrimidine derivatives 8a-d: compound 8c (substituted with COOEt group at position 3) has in vitro inhibitory activity more than 8a (substituted with COCH3 group at position 3). Cisplatin 0.95 ± 0.9 1.4 ± 1.1 11a 7.45 ± 0.7 9.78 ± 0.5 3a 32.6 ± 2.8 45.9 ± 3.1 11b 35.1 ± 10.8 20.1 ± 9.1 6 2.81 ± 0.9 2.99 ± 1.8 15 13.8 ± 1.4 19.0 ± 8.1 8a 326 ± 6.7 376 ± 10.2 17 7.33 ± 7.5 5.69 ± 9.8 8b 120 ± 12.1 159 ± 9.8 19 24.6 ± 11.8 25.5 ± 7.9 8c 3.45 ± 5.6 6.54 ± 8.2 21 9.0 ± 10.8 12.4 ± 8.9 8d 59.5 ± 0.6 24.7 ± 2.9
